Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have chosen to take part voluntarily and are willing to sign a consent form.
• People who have been confirmed by lab testing (cell or tissue samples) to have a type of lung cancer called non-small cell lung cancer (NSCLC) that has spread to lymph nodes on the opposite side of the chest from the main tumour, classified as stage IIIB or IIIC, and who have not yet received any treatment for it — staging must have been confirmed using specific scan types (PET/CT, or a chest/abdomen CT scan with contrast plus a bone scan and brain MRI).
• People whose lung tumour has been assessed by a specialist team, including a chest surgeon, as potentially removable by surgery.
• People who are generally well enough to carry out light activity and care for themselves, as measured by a standard medical fitness scale (ECOG score of 0 or 1).
• People whose blood counts, kidney function, liver function, lung function, and blood clotting results all fall within the levels required by the trial (confirm specific values with the trial site).
• People aged between 18 and 75 years old.

Who may not be able to join:

• People with an active or suspected autoimmune disease — though certain conditions such as vitiligo, type 1 diabetes, or an underactive thyroid managed only with hormone replacement and showing no active signs may still be considered (confirm with trial site).
• People who have been taking steroid tablets (above a low daily dose) or other medicines that suppress the immune system within the 14 days before enrolling.
• People who have previously had radiotherapy (radiation treatment) to the chest area.
• People who have significant active bleeding at the time of treatment.
• People with serious heart, lung, liver, kidney, or blood system problems, or significant weight loss and muscle wasting, that the trial doctor judges would make chemotherapy and radiotherapy too risky.
• People who have had diabetes for more than 10 years with blood sugar levels that have not been well controlled.
• People with a history of a lung condition called interstitial lung disease, or inflammation of the lungs not caused by infection (non-infectious pneumonitis).
• People whose lung cancer has specific gene changes known as EGFR mutations or ALK fusion, which are detected through tumour testing.
• People who have had another active cancer within the past 2 years — with possible exceptions for certain fully treated skin cancers or very early-stage cancers, or for people whose other cancer has been in complete remission for 2 or more years and requires no further treatment during this trial (confirm with trial site).
• People whose medical, psychological, or physical condition, in the trial doctor's judgement, would prevent them from completing the trial or understanding the study information.
• People who have previously been treated with certain types of immunotherapy drugs that work on immune checkpoint or T-cell pathways (such as anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 medicines).
• People with active Hepatitis B or active Hepatitis C infection, based on specific blood test results (confirm with trial site).
• People known to be HIV positive or to have AIDS.
• People with a known allergy to sintilimab (the immunotherapy drug used in this trial), any of the chemotherapy medicines used, or their ingredients.
• People who are pregnant or currently breastfeeding.
• People whose cancer has spread to lymph nodes above the collarbone or to other parts of the body (distant metastasis).

Important: Always verify eligibility with the trial site directly before applying.